Cutaneous calcinosis
Also known as: Calcinosis cutis, Skin, Dermis, Cutis, Dermal
Methodology & AI Transparency ⓘ
Cutaneous calcinosis Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Within Dermatology: Acne, Eczema, Psoriasis & Rosacea practice, Cutaneous calcinosis (also termed Calcinosis cutis or Skin) (ICD-10 L94.2) is stratified through dermoscopy or punch in Cutaneous calcinosis (L94.2: biopsy when atypical), pairing targeted symptom control with longitudinal Fasting Lipids & in Cutaneous calcinosis (L94.2: ALT (if systemic) surveillance.
- 2 Real-world patient consensus: Mapped to Dermatology: Acne, Eczema, Psoriasis & Rosacea under ICD-10-CM L94.2 for Cutaneous calcinosis clinical workups.
- 3 Typical cash cost range: Clinicians assessing Cutaneous calcinosis focus on epidermal barrier filaggrin/ceramide in Cutaneous calcinosis (L94.2: disruption) and targeted history.
- 4 Top reported side effects / signs: Longitudinal Cutaneous calcinosis monitoring tracks Affected Body Surface in Cutaneous calcinosis (L94.2: Area (BSA /) toward Clear or Almost Clear (IGA 0–1) (L94.2).
Ask our AI Specialists anything about Cutaneous calcinosis
What Is Cutaneous calcinosis?
Within Dermatology: Acne, Eczema, Psoriasis & Rosacea practice, Cutaneous calcinosis (also termed Calcinosis cutis or Skin) (ICD-10 L94.2) is stratified through dermoscopy or punch in Cutaneous calcinosis (L94.2: biopsy when atypical), pairing targeted symptom control with longitudinal Fasting Lipids & in Cutaneous calcinosis (L94.2: ALT (if systemic) surveillance.
Pathophysiology, Underlying Causes & Clinical Presentation
In Cutaneous calcinosis (L94.2), physiological disruption stems from epidermal barrier filaggrin/ceramide in Cutaneous calcinosis (L94.2: disruption), informing Dermatology: Acne, Eczema, Psoriasis & Rosacea protocols that track Fasting Lipids & in Cutaneous calcinosis (L94.2: ALT (if systemic) (Within baseline reference limits (L94.2)).
Common Symptoms & Clinical Signs
- • Presentation of Cutaneous calcinosis (L94.2): post-inflammatory hyperpigmentation, facial in Cutaneous calcinosis (L94.2: flushing, or pitted)
- • Secondary Cutaneous calcinosis clinical sign: recurrent flares triggered in Cutaneous calcinosis (L94.2: by UV exposure,)
- • Symptom flares in Cutaneous calcinosis correlating with Affected Body Surface in Cutaneous calcinosis (L94.2: Area (BSA /) deviation outside Clear or Almost Clear (IGA 0–1) (L94.2)
- • Functional skin & dermatology impact requiring dermoscopy or punch in Cutaneous calcinosis (L94.2: biopsy when atypical) evaluation (L94.2)
Cutaneous calcinosis Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | L94.2 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Dermatology: Acne, Eczema, Psoriasis & Rosacea | NLM Clinical Tables |
| Diagnostic / Lab Marker: Affected Body Surface in Cutaneous calcinosis (L94.2: Area (BSA /) | Clear or Almost Clear (IGA 0–1) (L94.2) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Fasting Lipids & in Cutaneous calcinosis (L94.2: ALT (if systemic) | Within baseline reference limits (L94.2) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: 25-Hydroxy Vitamin D in Cutaneous calcinosis (L94.2: & hs-CRP) | 25(OH)D 40–65 ng/mL (L94.2) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Cutaneous calcinosis
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Lolium Perenne Standardized Perennial Rye Grass • RxCUI RXN-49643379-2512 | Standardized Pollen Allergenic Extract | 83% | $0.3600 | $ 23.08 /mo |
| Klayesta (Nystatin Topical Powder) Klayesta • RxCUI RXN-B42806186 | Polyene Antifungal | 94% | $0.2525 | $ 26.68 /mo |
| Nystatin Mycostatin, Nystop • RxCUI 543546 | Polyene Antifungal | 89% | $0.2525 | $ 6.64 /mo |
| Poa Pratensis Standardized Kentucky Blue (June) Grass • RxCUI RXN-49643393-2513 | Standardized Pollen Allergenic Extract | 84% | $2.6300 | $ 115.02 /mo |
| Nystatin and Triamcinolone Acetonide Nystatin and Triamcinolone Acetonide Generic • RxCUI 1053753 | Polyene Antifungal | 76% | $0.2203 | $ 17.42 /mo |
| Agrostis Alba Standardized Redtop Grass • RxCUI RXN-49643309-2934 | Standardized Pollen Allergenic Extract | 78% | $1.1800 | $ 56.29 /mo |
| Cynodon Dactylon Standardized Bermuda Grass • RxCUI RXN-49643342-3007 | Standardized Pollen Allergenic Extract | 87% | $2.6600 | $ 116.23 /mo |
| Ketoconazole Ketoconclear Cream, Nizoral • RxCUI 197853 | Azole Antifungal | 94% | $0.0754 | $ 7.28 /mo |
| Bexarotene Targretin • RxCUI 308725 | Retinoid | 84% | $1.6000 | $ 81.69 /mo |
| Festuca Elatior Standardized Meadow Fescue Grass • RxCUI RXN-49643350-2936 | Standardized Pollen Allergenic Extract | 84% | $3.4900 | $ 149.85 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Cutaneous calcinosis)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Noninferiority of oral vs subcutaneous: What a 6,253-Participant Study Found Both forms of semaglutide effectively improve blood sugar control in T2D. Polish archives of internal medicine • 2025-12-18 • Meta-Analysis | N = 6,253 | 94/100 | PMID 41117588 ↗ |
| New Insights on Efficacy of high-dose atorvastatin or rosuvastatin loading in patients with acute: What a 6,291-Participant Study Found A high-dose loading of statins before PCI in patients with ACS reduces MACCE and reduces the risk of MI with no impact on mortality at 30 days. European journal of clinical pharmacology • 2022-01-15 • Meta-Analysis | N = 6,291 | 94/100 | PMID 34423376 ↗ |
| New Insights on Benefits and safety of Subcutaneous Vedolizumab in Patients With Moderately to: What a 275-Participant Study Found Vedolizumab SC is an effective and safe maintenance therapy in patients with CD who responded to two infusions of vedolizumab intravenous induction therapy. Journal of Crohn's & colitis • 2022-01-28 • Phase III Randomized Trial | N = 275 | 93/100 | PMID 34402887 ↗ |
| New Insights on Effect of Subcutaneous Semaglutide vs Placebo as an add-on booster to Intensive: What a 611-Participant Study Found Of 611 randomized participants (495 women [81.0%], mean age 46 years [SD, 13], body weight 105.8 kg [SD, 22.9], and body mass index 38.0 [SD, 6.7]), 567 (92.8%) completed the trial, and 505 (82.7%) were receiving treatment at... JAMA • 2021-04-13 • Phase III Randomized Trial | N = 611 | 93/100 | PMID 33625476 ↗ |
| New Insights on Benefits and safety of Subcutaneous Anifrolumab in Systemic Lupus Erythematosus:: What a 367-Participant Study Found Consistent with the well-established profile of intravenous anifrolumab, subcutaneous anifrolumab demonstrated significant, clinically meaningful treatment benefits when added to standard therapy, and an acceptable safety... Arthritis & rheumatology (Hoboken, N.J.) • 2026-06-15 • Phase III Randomized Trial | N = 367 | 93/100 | PMID 41466456 ↗ |
Cutaneous calcinosis Patient Community & “People Like Me” Threads
Filter Cutaneous calcinosis community threads and patient logs by age, biological sex, dosage, and treatment duration.